Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of recombinant L-asparaginase versus Asparaginase medac in previously untreated childhood acute lymphoblastic leukemia
2006-003180-31Phase 3Completed
- Sponsor
- medac GmbH
- Start
- Mar 2008
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of asparaginase escherichia coli in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by medac GmbH. Primary endpoint: Number of patients with complete asparagine depletion in serum during induction treatment. Started Mar 2008; status: completed.
02
Drugs
asparaginase escherichia coli
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2006-003180-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003180-31.